top of page
MEMBERS
Min-Chae Kang, BSN.
RESEARCHER
AFFILIATION
National Cancer Center
DEPARTMENT
Targeted Therapy Branch
EDUCATION
• 2019-2023 BSN Chung-Ang university, Seoul, Korea
• 2024-present MS Major in preventive medicine, Hanyang University, Seoul, Korea (expected)
CONTACT
PUBLICATIONS
• Lee EG, Kim KH, Kim SB, Chae YC, Kang MC, et al. Clinical Applications of Blood-Derived Extracellular Vesicle Biomarkers in Breast Cancer: A Scoping Review. Int J Mol Sci. 2026;27(10):4649. doi:10.3390/ijms27104649
• Kim S, Lee S, Kim H, Kang SJ, Chae H, Kim BJ, Kong J, Kang MC, Kim TM, Kong SY. Delineation of the heterogeneity underlying genomic instability in hereditary breast cancers reveals four disease subtypes. Exp Mol Med. 2026;58(4):1254-1268. doi:10.1038/s12276-026-01693-4. (IF: 8.72; Q1)
• Kang MC, Jung SY, Lee S, et al. Causal Attributions in Patients with Breast and Gynecological Cancers: A Scoping Review. Psychooncology. 2025;34(8):e70253. doi:10.1002/pon.70253
• Kang MC, Lee S, Kim H, et al. PALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350+5G>A variant in 3987 Korean cancer patients. ESMO Open. 2025;10(3):104132. doi:10.1016/j.esmoop.2024.104132
• Park JE, Kang MC, Lee T, et al. Prevalence Estimation of the PALB2 Germline Variant in East Asians and Koreans through Population Database Analysis. Cancers (Basel). 2024;16(19):3318. Published 2024 Sep 28. doi:10.3390/cancers16193318
• Kang MC, Kong SY (*co-first), Park SY, et al. Case report: Extraskeletal Ewing sarcoma with a germline pathogenic variant of SMARCA4. Front Oncol. 2024;14:1422605. 2024 Oct 8. doi:10.3389/fonc.2024.1422605
• Kang MC, Park JE (*co-first), Jang MA, et al. PALB2 생식세포 병원성 변이의 임상적 의의. Lab Med Online. 2024;14(4):311–320.
• Yoo KH, Kang MC (*co-first), Jung YR, et al. MUTYH 생식세포 유전자 변이의 임상적 의의. Lab Med Online. 2023;13(4):301–307.
AWARDS
• Outstanding Oral Award, Korean Society for Genetic Diagnostics (KSGD), May 2026
• Encouragement Award, K-CURE Cancer Public Data Challenge, Nov 2025 (Title: Survival Prognosis Analysis of Germline BRCA1/2 and NGS-Based Gene Variants in High-Risk Korean Hereditary Breast Cancer Patients)
• Young Investigator Award, Korean Society of Medical Oncology (KSMO), Sep 2025
• Best Poster Award, Asian Oncology Society (AOS) - Korean Cancer Association (KCA), Jul 2025
• Best Presentation Award, Korean Society for Cancer Prevention (KSCP), Jun 2025
• Outstanding Paper Award, Korean Society for Genetic Diagnostics (KSGD), Jun 2025
• Outstanding Poster Award, Korean Society for Genetic Diagnostics (KSGD), Jun 2025
• Outstanding Paper Award, Korean Society for Genetic Diagnostics (KSGD), Jun 2024
PRESENTATIONS
• Uptake and Patterns of Cascade Genetic Testing for Germline Pathogenic Variants in Families of 990 Patients with Hereditary Cancer. Oral presented at: Korean Society of Genetic Diagnostics (KSGD); May 21, 2025; Seoul, Korea. (Awarded: Outstanding Oral Award)
• Reclassification of an NF1 Variant from a Variant of Uncertain Significance to Likely Pathogenic in a Patient with Multiorgan Cancer: A Case Report. Poster presented at: Korean Genome Organization (KOGO) Conference; Feb 5, 2026; Hongcheon, Korea.
• Comparative Validation of BOADICEA, BRCAPRO, Myriad, and KOHCal Models for Predicting Germline Pathogenic Variants in 1,275 Korean Women with Breast and Ovarian Cancer. Poster presented at: The Korean Society of Cancer Prevention 2025 Annual Meeting; Nov 28, 2025; Korea.
• Validation of BOADICEA for Predicting Germline Pathogenic Variant Carriers in Eight Breast and Ovarian Cancer Susceptibility Genes among 1,275 Korean Female Patients with Breast or Ovarian Cancer. Oral presented at: LMCE 2025 (Laboratory Medicine International Conference); Oct 2025; Incheon, Korea.
• Real-World Data on Genetic Testing Preferences in 1,850 Korean Breast Cancer Patients Following Genetic Counseling: Who Chooses Next-Generation Sequencing over BRCA1/2 Testing? Poster presented at: Korean Society of Medical Oncology (KSMO); Sep 2025; Seoul, Korea. (Awarded: Young Investigator Award)
• Exploring Illness Representations and Psychological Outcomes in 1,045 Korean Women with Cancer Undergoing Genetic Evaluation for Hereditary Breast and Ovarian Cancer Syndrome. Poster presented at: Asian Oncology Society (AOS) and the Korean Cancer Association (KCA); Jul 3, 2025; Seoul, Korea. (Awarded: Best Poster Award)
• Causal Attribution in 1,104 Korean Cancer Patients Who Underwent Genetic Testing. Oral presentation at: Korean Society for Cancer Prevention; Jun 26, 2025; Oak Valley, Korea. (Awarded: Best Presentation Award)
• Temporal Impact of Public Events and Policy Changes on Genetic Testing Uptake: A Multi-Intervention Interrupted Time Series Analysis. Poster presented at: Korean Society of Genetic Diagnostics (KSGD); Jun 19, 2025; Seoul, Korea. (Awarded: Outstanding Poster Award)
• Causal Attribution in Korean Cancer Patients Who Underwent Genetic Testing: What Caused “My” Cancer? Poster accepted for presentation at: AACR Annual Meeting; Apr 27, 2025; Chicago, USA.
• Clinical Features of MUTYH c.934-2A>G Germline Variant in Korea. Poster presented at: Korean Cancer Association Annual Meeting; Jun 21, 2024; Seoul, Korea.
• Prevalence and Clinical Characteristics of PALB2 Germline Pathogenic Variants in Korean Cancer Patients. Oral presented at: Korean Society of Genetic Diagnostics (KSGD); Jun 14, 2024; Seoul, Korea.
• Prevalence and Risk Factors of PALB2 Germline Pathogenic Variants. Poster presented at: American Association for Cancer Research (AACR) Meeting; Apr 10, 2024; San Diego, USA.
• A Case Series: Cancer Patients with Germline Pathogenic Variants of MRE11A. Poster presented at: Korean Genome Organization (KOGO) Conference; Feb 1, 2024; Hongcheon, Korea.
• Clinical Features of PALB2 c.3350+5G>A Germline Pathogenic Variant in Korea. Poster presented at: LMCE 2023 (Laboratory Medicine International Conference); Oct 18, 2023; Suwon, Korea.
• A Case of Extraskeletal Ewing Sarcoma with a Germline Pathogenic Variant of SMARCA4. Poster presented at: Korean Society of Medical Oncology (KSMO) Annual Meeting; Sep 7, 2023; Seoul, Korea.
bottom of page